Ubs Asset Management Americas Inc Alkermes Plc. Transaction History

Ubs Asset Management Americas Inc

  • $381 Billion
  • Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 405,382 shares of ALKS stock, worth $11.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
405,382
Previous 260,876 55.39%
Holding current value
$11.4 Million
Previous $6.29 Million 80.47%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$23.01 - $28.55 $3.33 Million - $4.13 Million
144,506 Added 55.39%
405,382 $11.3 Million
Q2 2024

Aug 13, 2024
BUY
$23.21 - $27.24 $1.52 Million - $1.78 Million
65,434 Added 33.48%
260,876 $6.29 Million
Q1 2024

May 15, 2024
BUY
$26.4 - $32.56 $146,150 - $180,252
5,536 Added 2.92%
195,442 $5.29 Million
Q4 2023

Feb 14, 2024
BUY
$23.37 - $28.68 $174,013 - $213,551
7,446 Added 4.08%
189,906 $5.27 Million
Q3 2023

Nov 13, 2023
SELL
$27.17 - $31.97 $839,987 - $988,384
-30,916 Reduced 14.49%
182,460 $5.11 Million
Q1 2023

May 15, 2023
BUY
$25.31 - $29.02 $603,668 - $692,156
23,851 Added 12.58%
213,376 $6.02 Million
Q4 2022

Feb 14, 2023
BUY
$21.94 - $26.24 $139,757 - $167,148
6,370 Added 3.48%
189,525 $4.95 Million
Q3 2022

Nov 14, 2022
SELL
$22.0 - $31.87 $875,006 - $1.27 Million
-39,773 Reduced 17.84%
183,155 $4.09 Million
Q2 2022

Aug 12, 2022
BUY
$26.4 - $30.54 $11,800 - $13,651
447 Added 0.2%
222,928 $6.64 Million
Q1 2022

May 16, 2022
SELL
$23.07 - $27.99 $5.39 Million - $6.54 Million
-233,647 Reduced 51.22%
222,481 $5.85 Million
Q4 2021

Feb 14, 2022
SELL
$21.47 - $32.08 $4.23 Million - $6.33 Million
-197,201 Reduced 30.18%
456,128 $10.6 Million
Q3 2021

Nov 15, 2021
BUY
$23.37 - $32.13 $2.63 Million - $3.62 Million
112,739 Added 20.85%
653,329 $20.1 Million
Q2 2021

Aug 16, 2021
SELL
$18.78 - $25.15 $6.91 Million - $9.25 Million
-367,983 Reduced 40.5%
540,590 $13.3 Million
Q1 2021

May 14, 2021
BUY
$18.21 - $23.2 $7.47 Million - $9.52 Million
410,481 Added 82.41%
908,573 $17 Million
Q4 2020

Mar 01, 2021
BUY
$15.39 - $22.1 $678,622 - $974,499
44,095 Added 9.71%
498,092 $9.94 Million
Q3 2020

Nov 13, 2020
BUY
$16.16 - $20.66 $3.78 Million - $4.84 Million
234,080 Added 106.44%
453,997 $7.52 Million
Q2 2020

Aug 14, 2020
SELL
$13.31 - $19.41 $296,666 - $432,629
-22,289 Reduced 9.2%
219,917 $4.27 Million
Q1 2020

May 15, 2020
BUY
$13.06 - $21.24 $267,507 - $435,058
20,483 Added 9.24%
242,206 $3.49 Million
Q4 2019

Feb 14, 2020
SELL
$17.29 - $21.74 $14.2 Million - $17.9 Million
-822,210 Reduced 78.76%
221,723 $4.52 Million
Q3 2019

Nov 14, 2019
SELL
$19.51 - $24.28 $667,437 - $830,618
-34,210 Reduced 3.17%
1,043,933 $20.4 Million
Q2 2019

Aug 15, 2019
BUY
$21.47 - $37.33 $488,850 - $849,966
22,769 Added 2.16%
1,078,143 $0
Q1 2019

May 14, 2019
SELL
$28.4 - $36.49 $425,687 - $546,948
-14,989 Reduced 1.4%
1,055,374 $0
Q4 2018

Feb 13, 2019
BUY
$27.94 - $44.61 $559,191 - $892,824
20,014 Added 1.91%
1,070,363 $31.6 Million
Q3 2018

Nov 14, 2018
SELL
$38.6 - $46.12 $4.08 Million - $4.88 Million
-105,824 Reduced 9.15%
1,050,349 $0
Q2 2018

Aug 14, 2018
SELL
$40.56 - $51.36 $625,232 - $791,714
-15,415 Reduced 1.32%
1,156,173 $0
Q1 2018

May 14, 2018
SELL
$53.61 - $67.26 $2.17 Million - $2.72 Million
-40,475 Reduced 3.34%
1,171,588 $0
Q4 2017

Feb 09, 2018
SELL
$47.69 - $55.39 $2.43 Million - $2.83 Million
-51,046 Reduced 4.04%
1,212,063 $0
Q3 2017

Nov 13, 2017
BUY
$49.16 - $54.45 $62.1 Million - $68.8 Million
1,263,109
1,263,109 $0

Others Institutions Holding ALKS

# of Institutions
360
Shares Held
181M
Call Options Held
175K
Put Options Held
96.6K
View Full List

About Alkermes plc.

ALKS Quotes by TradingView
  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.63B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email